68Ga-FAPI-04与18F-FDG PET/CT诊断卵巢癌的比较
本研究纳入79例卵巢癌患者(6例初诊评估、73例复发转移检测),比较68Ga-FAPI-04与18F-FDG PET/CT的诊断效能。68Ga-FAPI-04在全部病灶的靶本比更高,对腹膜转移的病灶分析敏感度更高(90.16% vs 60.66%,P<0.001),PCI评分更高,55.93%腹膜转移患者显示更广泛转移范围,7例(8.86%)分期上调,11例(13.92%)治疗策略改变。结论认为68Ga-FAPI-04 PET/CT在识别转移方面优于18F-FDG PET/CT,可能作为卵巢癌管理的补充手段。
要点
- 68Ga-FAPI-04 PET/CT对腹膜转移病灶分析敏感度高于18F-FDG(90.16% vs 60.66%,P<0.001)。
- 68Ga-FAPI-04的PCI评分中位数高于18F-FDG[6(4,12)vs 4(2,8),P<0.001]。
- 68Ga-FAPI-04使7例(8.86%)分期上调、11例(13.92%)治疗策略改变。
核心结论
- 68Ga-FAPI-04 PET/CT在识别卵巢癌转移方面优于18F-FDG PET/CT,可能作为卵巢癌患者管理的补充手段。
研究设计与样本
- 研究纳入79例卵巢癌患者,均行68Ga-FAPI-04与18F-FDG PET/CT,其中6例用于初诊评估、73例用于复发和转移检测;比较两种PET/CT的靶本比、SUVmax、阳性病灶数、视觉评估、PCI评分、分期/再分期及治疗策略,并分析诊断效能。
诊断标准与关键数值
- 腹膜转移患者分析敏感度:68Ga-FAPI-04 95.00% vs 18F-FDG 83.33%,P=0.065。
- 腹膜转移病灶分析敏感度:68Ga-FAPI-04 90.16% vs 18F-FDG 60.66%,P<0.001。
- PCI评分中位数:68Ga-FAPI-04 6(4,12)vs 18F-FDG 4(2,8),P<0.001。
- 视觉评估显示68Ga-FAPI-04在55.93%(33/59)腹膜转移患者中显示更大范围转移。
- 68Ga-FAPI-04使7例(8.86%,7/79)分期上调,两种扫描差异导致11例(13.92%,11/79)治疗策略改变。
临床应用与阅片要点
- 原文结论认为68Ga-FAPI-04 PET/CT在识别转移方面优于18F-FDG PET/CT,可能作为卵巢癌患者管理的补充手段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study assesses the diagnostic performance of 68Ga-FAPI-04 PET/CT compared to 18F-FDG PET/CT in primary, recurrent, and metastatic ovarian cancer.
METHODS: Seventy-nine ovarian cancer patients who performed 68Ga-FAPI-04 and 18F-FDG PET/CT were recruited. The target-to-background ratio (TBR), maximum standardized uptake value (SUVmax), the number of positive lesions, visual assessment, the peritoneal cancer index (PCI) score, staging/restaging, and treatment strategies were compared from the corresponding PET/CT. Additionally, we analyzed and contrasted the diagnostic efficacy in both scans.
RESULTS: Among all patients, 6 were assessed for initial assessment and 73 for recurrence and metastasis detection. For all lesions, 68Ga-FAPI-04 PET/CT demonstrated greater TBR than 18F-FDG PET/CT. 68Ga-FAPI-04 PET/CT demonstrated higher sensitivity for peritoneal metastases including patient-based and lesion-based analysis (95.00% vs. 83.33%, P = 0.065; 90.16% vs. 60.66%, P < 0.001) and a higher PCI score [median PCI: 6 (4, 12) vs. 4 (2, 8), P < 0.001]. According to the visual assessment, 68Ga-FAPI-04 PET revealed larger extent metastases in 55.93% (33/59) of the patients with peritoneal metastases. 68Ga-FAPI-04 was upstaged in 7 patients (8.86%, 7/79) and discrepancies in both scans caused treatment strategies to change in 11 patients (13.92%, 11/79).
CONCLUSION: 68Ga-FAPI-04 PET/CT outperforms 18F-FDG PET/CT in identifying metastases and can be a potential supplement for managing ovarian cancer patients.
引用
- Liu Y, Pan J, Jing F, et al. Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT in diagnosing ovarian cancer. Abdom Radiol (NY). 2024. PMID: 38937339. doi:10.1007/s00261-024-04469-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。